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a b s t r a c t
Mitochondria have a myriad of essential functions including metabolism and apoptosis. These chief
functions are reliant on electron transfer reactions and the production of ATP and reactive oxygen species
(ROS). The production of ATP and ROS are intimately linked to the electron transport chain (ETC). Electrons
from nutrients are passed through the ETC via a series of acceptor and donor molecules to the terminal
electron acceptor molecular oxygen (O2) which ultimately drives the synthesis of ATP. Electron transfer
through the respiratory chain and nutrient oxidation also produces ROS. At high enough concentrations
ROS can activate mitochondrial apoptotic machinery which ultimately leads to cell death. However, if
maintained at low enough concentrations ROS can serve as important signaling molecules. Various
regulatory mechanisms converge upon mitochondria to modulate ATP synthesis and ROS production.
Given that mitochondrial function depends on redox reactions, it is important to consider how redox
signals modulate mitochondrial processes. Here, we provide the ﬁrst comprehensive review on how redox
signals mediated through cysteine oxidation, namely S-oxidation (sulfenylation, sulﬁnylation), S-glutathio-
nylation, and S-nitrosylation, regulate key mitochondrial functions including nutrient oxidation, oxidative
phosphorylation, ROS production, mitochondrial permeability transition (MPT), apoptosis, and mitochon-
drial ﬁssion and fusion. We also consider the chemistry behind these reactions and how they are
modulated in mitochondria. In addition, we also discuss emerging knowledge on disorders and disease
states that are associated with deregulated redox signaling in mitochondria and how mitochondria-
targeted medicines can be utilized to restore mitochondrial redox signaling.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.
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Introduction
Mitochondria can be a major source of cellular ROS which
inherently depends on the metabolic “state” of mitochondria [1].
However, in order to understand mitochondrial ROS production, it is
important to examine aerobic metabolism in detail. Nutrients
(e.g. glucose, fatty acids, amino acids) are converted into metabolic
intermediates (e.g. pyruvate, acetyl-CoA, oxaloacetate, 2-oxogluta-
rate) which are then systematically metabolized and decarboxylated
by eight different enzymes in the tricarboxylic acid (TCA) cycle
(Fig. 1). The decarboxylation steps are coupled to the transfer of
electrons to NADþ producing NADH [2]. Complex I (NADH:ubiqui-
none oxidoreductase) subsequently oxidizes NADH and the liberated
electrons are passed to ubiquinone (Q) generating ubiquinol (QH2)
[3]. Electrons from Complex II (succinate dehydrogenase; SDH),
electron transfer ﬂavoprotein oxidoreductase (ETF-QO), dihydroor-
otate dehydrogenase, and FAD-linked glycerol-3-phosphate dehy-
drogenase can also feed electrons into the Q pool [4–7]. The
electrons are then passed to Complex III through cytochrome C
and on to Complex IV which then reduces the terminal electron
acceptor O2 into H2O (Fig. 1) [8]. The most important aspect of this
process is the redox potentials of NADH (Eo
0 ¼ 340 mV), and O2
(Eo
0 ¼ þ810 mV). Due to this redox difference electron ﬂow from
NADH through the well-ordered prosthetic groups located within
the individual respiratory complexes to O2 at Complex IV is an
energetically favorable process. According to Peter Mitchell0s Che-
miosmotic Theory, the energetically favorable transfer of electrons
from NADH to O2 through the respiratory complexes is coupled to
the pumping of protons through Complexes I, III, and IV into the
intermembrane space. This creates a temporary form of stored
energy, namely, the protonmotive force (PMF) which is used by
Complex V to produce ATP from ADP and Pi. Hence, the production
of ATP from nutrient oxidation in mitochondria depends on a
multitude of redox reactions.
Oxygen can only accept one electron at a time during its
reduction to H2O. Electrons from Complexes I and III (and Complex
II depending on experimental conditions) can “spin-off” prema-
turely, univalently reducing O2 to produce the proximal ROS
superoxide anion radical (O2) [9]. O2 is then quickly dismutated
to H2O2 which is considered to be a chief ROS signaling molecule
due to its longer half-life and capacity to diffuse through mem-
branes. Complexes I and III remain the most well characterized
sources of O2 in mitochondria [10]. Other mitochondrial sources
of O2 and H2O2 include 2-oxoglutarate dehydrogenase (Odh),
Fig. 1. Aerobic respiration, oxidative phosphorylation, and chemiosmotic theory: nutrients in the form of pyruvate (generated from glucose via glycolysis in the cytoplasm),
acetyl-CoA (produced from pyruvate or generated by fatty acid oxidation), or amino acids enter the tricarboxylic acid (TCA) and are systematically oxidized by the concerted
action of 8 different enzymes. Carbon oxidation is coupled to decarboxylation reactions which yield the necessary electrons required to drive oxidative phosphorylation
(OXPHOS). Electrons from the TCA cycle are transferred to NAD generating the electron carrier NADH which is then oxidized by Complex I. Electrons can also be provided by
Complex II which oxidizes succinate to fumarate in the TCA cycle. Electrons then ﬂow through a series of redox active prosthetic groups and molecules to the terminal
electron O2 at Complex IV. The favorable energy change associated with electron ﬂow is coupled to the pumping of protons through Complexes I, III, and IV into the
intermembrane space. The protons are then transported back into the matrix by ATP synthase which couples the favorable energy change of proton transfer to the
production of ATP from ADP and Pi. This is referred to as “coupled” respiration or OXPHOS. ATP is then exported into the cytoplasm to do “work” in the cell. The antiporter
ANT is responsible for exporting ATP in exchange for ADP. The potential difference created by nutrient oxidation can be “uncoupled” from OXPHOS by MIM proteins ANT and
UCP for the purpose of thermogenesis or controlling mitochondrial ROS production. Dotted line: represents ﬂow of electrons and protons. Red circles: represent major sites for
ROS production in mitochondria. Note that the ROS species is not deﬁned in the ﬁgure and that other relevant sources of ROS, dihydroorotate dehydrogenase, sn-glycerol-3-
phosphate dehydrogenase (mGPDH), electron transfer ﬂavoprotein:ubiquinol oxidoreductase, p66shc/Cytochrome C, Mia40p/Erv1p, have been excluded for simplicity. Pdh;
pyruvate dehydrogenase, PC; pyruvate carboxylase, CS; citrate synthase, Acn; aconitase, Idh; isocitrate dehydrogenase, Odh; 2-oxoglutarate dehydrogenase, SCS; succinyl-
CoA synthase, Fum; fumarase, Mdh; malate dehydrogenase, I; Complex I, II; Complex II, III; Complex III, IV; Complex IV, V; Complex V, ANT; adenine nucleotide translocase,
UCP; uncoupling protein, Q; quinone, C; cytochrome C.
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pyruvate dehydrogenase (Pdh) [11], dihydroorotate dehydrogen-
ase, sn-glycerol-3-phosphate dehydrogenase (mGPDH), electron
transfer ﬂavoprotein:ubiquinol oxidoreductase, p66shc/Cyto-
chrome C, Mia40p/Erv1p, and succinate dehydrogenase (Complex
II) (reviewed in [10]). These enzymes can contribute signiﬁcantly
to total mitochondrial ROS production and can produce O2 or
H2O2 or both which depends on experimental conditions and
energetic substrates used [10,12]. H2O2 emitted frommitochondria
modulates insulin release, insulin signaling, the hypoxic response,
adipocyte differentiation, regulation of cell cycle, and T cell
receptor-initiated cell signaling [13–17]. H2O2 exerts its effects by
reversibly oxidizing protein cysteine thiols (–SH) to sulfenic acid
(–SOH). A protein cysteine thiol that can be reversibly oxidized by
H2O2 is referred to as a “redox switch”. However, the signaling
functions of ROS are not limited to just H2O2. Even O2 has also
been shown to have a signaling role in cells due to its capacity to
dismantle Fe–S clusters [18,19]. It has also recently been shown
that O2 increases and decreases “stochastically” with a periodi-
city of 20–40 s. The periodicity of O2 “ﬂashes” depends on the
metabolic state of mitochondria and has been suggested to play an
important role in mitochondrial permeability transition and
induction of apoptosis [20]. It is important to note that the
existence of periodic O2 “ﬂashes” frommitochondria has recently
been challenged since the cyclic permuted YFP (cpYFP) probe used
to detect stochastic changes in O2 production by mitochondria is
also highly sensitive to changes in pH [21]. Thus, it has been
questioned whether the periodic changes in cpYFP are due to
changes in O2 production or changes in pH [22]. Indeed, the
actual mechanism by which cpYFP interacts with O2 has not
been resolved. In addition, it has been suggested that cpYFP relies
on protein cysteine thiols to interact with O2 which is unlikely
given the slow rate of reaction between O2 and protein cysteine
thiols. Thus, the existence of O2 “ﬂashes” and their potential role
in signaling needs to be carefully re-examined.
Using oxyradicals as signaling molecules can be dangerous
since their accumulation can lead to production of the dreaded
hydroxyl radical (OH), a highly reactive species that indiscrimi-
nately oxidizes biological macromolecules. But even mitochondrial
O2 and H2O2 can have harmful effects if they accumulate to a
high enough concentration. At high enough levels, H2O2 can
oxidize –SOH to sulﬁnic (–SO2H) and sulfonic (–SO3H) acids which
renders proteins irreversibly deactivated [23]. Similarly, O2 dis-
assembles Fe–S clusters in a variety of TCA cycle enzymes and in
respiratory complexes [24] and can also combine with nitric oxide
(NO) to form the highly toxic species peroxynitrite (ONOO) [25].
Oxidative stress due to H2O2 or O2 is associated with a number of
pathologies, neurological disorders, and metabolic diseases. How-
ever, despite the ever present threat of oxidative stress, damage,
and death, mitochondria continue to employ ROS for intra and
intercellular signaling.
As illustrated above, it is very clear that mitochondrial ATP and
ROS production are intimately linked [26]. The production of ATP
over ROS (or vice versa) ultimately depends on electron transfer
through the respiratory chain, nutrient oxidation, nutrient avail-
ability, the electronchemical proton gradient across the mitochon-
drial inner membrane (MIM), the availability of ADP, and even the
structure and morphology of mitochondria [1,27–30]. A number of
different control mechanisms converge upon mitochondria to
adjust the output of ATP and ROS. These include allosteric control,
covalent modiﬁcation, protein synthesis, protein degradation, and
formation of respirasomes [31–35]. However, over the past decade,
there has been a surge in the number of articles published on the
topic of redox control of mitochondrial proteins. Various types of
redox modiﬁcations and switches, including S-oxidation (sulfeny-
lation and sulﬁnylation), S-glutathionylation, and S-nitrosylation
converge upon mitochondria to regulate a number of processes
ranging from OXPHOS to mitochondrial morphology to cell death.
However, very few reviews have actually covered the role of redox
switches in the control of mitochondrial function in detail
[23,36,37]. This is surprising as mitochondria use redox reactions
to drive all of its functions. Mitochondria also harbor a micro-
environment that favors redox signaling via cysteine oxidation
reactions. Thus, mitochondria are also a “hotbed” for regulation by
redox. In the following review, what is known about how
mitochondrial biology can be regulated by redox switches will
be surveyed. We will cover a broad range of subjects including the
different types of reactions, why redox signaling is so prevalent in
mitochondria, the role of redox switches in controlling mitochon-
drial function and apoptosis, and the association of deregulated
mitochondrial redox signaling in pathologies and how these
pathways can be targeted for therapeutic intervention. It is
important to note that sources of mitochondrial O2 and H2O2,
antioxidant defense systems, and mechanisms that control mito-
chondrial O2 and H2O2 production will not be discussed since a
number of reviews have already covered these very important
topics [9,38–40].
Protein cysteine modiﬁcations in mitochondria
Cysteine accounts for 2% of the amino acid content of cells
(protein-bound, peptide-bound, free) making it the least utilized
amino acid in biology [41]. Despite its limited use, it is one of the
most conserved amino acids in proteins. This can be attributed to
its unique physical properties which allow cysteine to fulﬁll very
important functions in cells. Sulfur is large, polarizable, and
electron rich and is thus very reactive and able to adopt multiple
oxidation states [42,43]. Cysteine residues are used in enzyme
active sites and play structural roles which include iron–sulfur
(Fe–S) assembly, heme, and zinc ﬁnger motifs [44–46]. Cysteine SH
can also react with neighboring SH groups to form a disulﬁde bridge,
an important structural component for secreted proteins [47].
Cysteine SH groups are also found on the surface of proteins making
contact with the surrounding aqueous environment. This particular
group of solvent exposed or “free” cysteine residues can be subjected
to a range of redox-sensitive modiﬁcations (outlined below). Mod-
iﬁcation of a solvent exposed SH group depends on its ability
to ionize and form a very nucleophilic thiolate anion (S) [48].
Formation of S is governed by the pKa of cysteine SH which is
inﬂuenced heavily by the surrounding microenvironment. At neutral
pH, cysteines have a pKa of 8.3 meaning it will be in a protonated
and unreactive state [49]. Exposure to a more alkaline environment
can substantially increase the probability that a cysteine SH will
adopt a deprotonated state [50]. Adjacent positively charged amino
acids can also substantially decrease the pKa of cysteine thiols,
rendering them more reactive. The presence of other adjacent
positive charges such as the partial positive charge of an α-helix
dipole or the nitrogen in the peptide backbone can also decrease the
pKa of cysteines [51]. For instance, the catalytic cysteines in glutar-
edoxin (Grx) isoforms 1 and 2 adopt a very low pKa (Grx1, cytosolic
isoform, pKa3.5 and Grx2, mitochondrial matrix isoform, pKa4.6)
due to close proximity of a lysine residue and the N-terminus of an α-
helix [52,53]. Likewise, neighbouring negative charges can increase
the pKa which is the case for reduced glutathione (GSH) which has a
pKa of 8.8 [49]. As mentioned SH reactivity also inﬂuences whether
or not it can adopt other oxidation states; e.g. be reactive enough to
sense changes in redox through interactions with H2O2. An excellent
example of this is peroxiredoxin (Prx) which uses a catalytic or
“peroxidatic” cysteine (Cysp), which has an estimated pKa of 5–6, to
metabolize H2O2 with exquisite efﬁciency [49,54]. Steric hindrance
also plays a part in cysteine thiol reactivity since cysteine oxidation
reactions are nucleophilic substitution (SN2) reactions [55,56]. Thus,
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it is clear that the surrounding microenvironment will dictate
whether or not a thiolate will be reactive enough to undergo
modiﬁcation which may also aid in dictating the selectivity for thiol
modiﬁcation.
These basic principles in SH chemistry and reactivity are highly
relevant to mitochondria. This is in light of the unique physical
properties of mitochondria. As outlined in the introduction, the
chief functions of mitochondria are dependent on the pumping of
protons from the matrix to the intermembrane space. This
effectively alkalinizes the matrix environment which has a tre-
mendous impact on mitochondrial redox potential and thiol
ionization. For example, the calculated midpoint potential for
GSH to glutathione disulﬁde (GSSG) ratio in the cytosol is
240 mV [57]. Since redox potentials are inﬂuenced by pH the
alkalinity of the matrix environment lowers the potential even
further (2GSH/GSSGmitochondria¼280 to 340 mV) [58]. Based on
this it is very probable that protein cysteine residues in the
mitochondrial matrix will exist in an ionized state. The mitochon-
drial proteome is also very rich in protein thiols. The estimated
concentration of exposed protein thiols in mitochondria is 60–
90 mM [59]. This actually makes protein cysteine residues the
most concentrated thiol in mitochondria. In conjunction with
these key properties mitochondria are also a major source for
O2 and H2O2 and contain high amounts of GSH (5 mM) which
are both required for redox signaling. Mitochondria are also a
major target for nitric oxide (NO) signaling and S-nitrosylation
[37,60]. Notably mitochondria have been reported to harbor NO
synthase (NOS; speciﬁcally neuronal NOS isoform) however; this
remains highly contentious (discussed below) [37]. Thus, it can be
concluded that mitochondria harbor a unique environment that
promotes thiol modiﬁcation.
S-oxidation (sulfenylation and sulﬁnylation)
In ROS-mediated signaling, the oxidation of protein cysteine SH
groups plays a central part in modulating protein function in
response to local changes in redox environment. It is important,
however, to note that all protein cysteine SH modiﬁcations are
S-oxidation reactions since they involve changes in valency. Thus,
cysteine SH oxidation by ROS is most often described as
S-oxidation or thiol oxidation. For our purposes here, we will
deﬁne S-oxidation speciﬁcally as sulfenylation and sulﬁnylation. It
is also important to identify which oxyradical species are respon-
sible for mediating these reactions. H2O2 is the most relevant
radical species in redox signaling. This is by virtue of its reactivity
with cysteine, capacity to diffuse through membranes, and its
prolonged half-life (relative to other oxyradicals). H2O2 signaling is
mediated through the formation of SOH [61]. In this reaction, the
highly nucleophilic S attacks H2O2, which results in formation of
SOH and OH [48]. Most protein cysteine SH groups react slowly
with H2O2 (20 M1 s1) [49]. This rate can be increased to as
high as 108 M1 s1 which is dependent on protein microenvir-
onment, pH, the pKa of the SH group, and presence of bulky groups
surrounding SH groups [62,63]. Due to their reactivity it has been
very difﬁcult to ascertain the pKa of SOH groups formed in
proteins. However, studies with small molecule sulfenic acids have
revealed that SOH groups have much lower pKa values than SH
groups [64,65]. Thus due to their lower pKa, it could be assumed
that SOH adopt an ionized state (SO) which makes them far more
reactive. This could account for the labile nature of SOH groups in
proteins explaining why they may be so difﬁcult to detect and
quantify. In addition, this also explains why SOH groups are
amenable to undergo a variety of different modiﬁcations as out-
lined in Fig. 2a [66].
SOH groups can participate in a plethora of side reactions (Fig. 2a).
For instance, SOH groups can quickly undergo S-glutathionylation if
GSSG are in the vicinity. S-glutathionylation of SOH groups is very
likely to proceed in mitochondria, given the small volume and high
concentration of GSH. Further, S-glutathionylation of SOH has an
important biological function in mitochondria, namely, the protec-
tion of cysteine residues from further oxidation when H2O2 levels are
Fig. 2. S-oxidation reactions and H2O2 signaling: (a) the various thiol oxidation
reactions. Thiols are deprotonated generating a reactive thiolate anion which can
then be oxidized by H2O2 to produce a SO . Due to their highly reactive nature,
SO undergoes a range of other reactions. Depending on the conditions, environ-
ment, and proximity of the SO to other reactive groups SO can be (1) further
oxidized by H2O2 to SO2H and SO3H, (2) react with amides on peptide backbones to
generate sulfenamides, (3) cross react with neighboring thiols to form intra or
intermolecular disulﬁde bonds which are reversed by Trx2, (4) undergo S-glu-
tathionylation which is reversed by Grx2, and (5) react with a sulfenic acid to
generate a thiosulﬁnate. (b) Lipoic acid residue on the E2 subunit of Odh can be
protected from further oxidation by S-glutathionylation. H2O2 oxidizes a sulfhydryl
moiety on the lipoate molecule generating SO which can be oxidized further
rendering Odh inactive. To protect from further oxidation, the SO is S-glutathio-
nylated which is reversed by Grx to regenerate an active enzyme. (c) Prx3 can
adopt multiple oxidation states. The peroxidatic Cys of Prx3 is oxidized by H2O2 to
yield SO which then reacts with a neighboring resolving Cys to produce a
disulﬁde bridge. The Cys residues are then reduced by Trx2 to regenerate active
Prx3. SO can also be further oxidized to SO2H which maintains Prx3 in an inactive
state for a longer period which allows H2O2 signaling to persist. Prx3 is reduced
back to an active enzyme complex by Srx. H2O2; hydrogen peroxide, SO; sulfenic
acid, SO2H; sulﬁnic acid, SO3H sulfonic acid, PSSG; protein glutathione disulﬁde
mixture, Odh; 2-oxoglutarate dehydrogenase, Grx; glutaredoxin, Prx3; peroxire-
doxin-3, Trx2; thioredoxin-2.
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higher than usual. For example, the sulfur residues on lipoate in the
E2 subunit of 2-oxoglutarate dehydrogenase (Odh), a TCA cycle
enzyme that couples 2-oxoglutarate decarboxylation to NADH pro-
duction, can be oxidized rapidly by H2O2 [67,68]. To avoid the
irreversible oxidation of SOH to SO3H, GSH is conjugated to SOH
forming a protein glutathione mixed disulﬁde (PSSG) which essen-
tially protects lipoate from further oxidation (Fig. 2b) [68]. Grx then
catalyzes the deglutathionylation of Odh reactivating the enzyme
[68]. Similar observations have been made for other mitochondrial
proteins including Complex I and adenine nucleotide translocator
(ANT) [69,70]. The absolute number of mitochondrial protein SH
groups that can form SOH has yet to be quantiﬁed. This may be
difﬁcult given that mitochondrial isolation protocols can result in
unwanted oxidation of cysteine residues. Oxidation of cysteines
during isolation can be prevented or minimized by the addition of
N-ethylmaleimide (NEM), an alkylating agent that forms a Michael
adduct with SH. Unfortunately, SOH groups are also very labile which
also makes them difﬁcult to quantify. Several methods have been
used to properly trap and quantify SOH groups. These methods
typically involve using dimedone molecules which react selectively
with SOH groups tagging them for quantiﬁcation [71]. Dimedone
probes have also been used to measure SH oxidation to SOH in
mitochondria [72]. However, it is possible to improve the efﬁcacy of
dimedone probes for quantiﬁcation of mitochondrial SOH levels. For
instance, triphenylphosphonium-tagged dimedone (TPP-dimedone)
molecules can potentially be developed and used to trap and quantify
mitochondrial SOH. TPP-dimedone could be administered in vivo
allowing more accurate quantiﬁcation of mitochondrial SOH. TPP is a
lipophilic cation that preferentially accumulates in mitochondria due
to large charge difference between the intermembrane space (posi-
tive) and matrix (negative) [73]. It is important to point out though
that TPP probes can potentially hinder mitochondrial metabolism by
uncoupling the proton gradient [74]. It is also important to acknowl-
edge that SOH can form from one electron reduction reactions. These
reactions involve the formation of a thiyl radical following exposure
to radiation [75]. O2 has also been shown to catalyze the one
electron reduction of low molecular weight thiols with a rate
constant of 103 M1 s1 however; this may be insigniﬁcant given
the rapid kinetics of superoxide dismutase (SOD; 108 M1 s1) [10].
SOH groups can also react with neighboring SH groups to form
intra or intermolecular disulﬁde bonds (Fig. 2a). This type of
reaction is particularly important for antioxidant enzymes like
Prx. In mitochondria, Prx3 is a homodimer with both subunits
aligned in a head-to-tail fashion with Cysp on the N-terminus and
the resolving cysteine (Cysr) on the C-terminus [54] (Fig. 2c). H2O2
quickly oxidizes Cysp producing SOH which then reacts with the
neighbouring Cysr forming an intermolecular disulﬁde bridge. The
catalytic cycle is completed by thioredoxin-2 (Trx2) and NADPH-
mediated reduction of the intermolecular disulﬁde bridge. SOH
groups can also react with other SOH groups to form thiosulﬁnates
or react with neighboring nitrogens to form sulfenamides [75]
(Fig. 2a). Thus, due to their highly reactive nature and nucleophilic
and electrophilic properties, SOH can participate in a broad range
of reactions. It is important to note though that it remains to be
determined if thiosulﬁnates or sulfenamides are actually formed in
mitochondria. Finally it is important to point out that a vast
majority of these reactions are reversible either through Trx
or Grx.
SOH can also undergo further oxidation by H2O2 (Fig. 2a). Since
SOH can participate in a number of side reactions, further oxida-
tion by H2O2 depends on protein microenvironment, presence of
GSH, and quantity of H2O2. Oxidation of SOH generates SO2H. This
reaction depends on the ionization of SOH and the nucleophilic
attack of H2O2 [48]. Hyperoxidation of SOH to SO2H is often
associated with oxidative stress [76]. However, it was recently
observed that sulﬁredoxin (Srx) can reduce SO2H back to SH in
Prx (Fig. 2c) [77]. Although Srx has only been shown to reduce
SO2H in Prx it would be important to ascertain if Srx has other
targets. Indeed, the reversible nature of SO2H would suggest that
sulﬁnic acid formation may be important for the redox regulation
of proteins. Tt has been found that 5% of the cysteines in soluble
rat liver proteins exist as SO2H [78]. In mitochondria SO2H
formation is crucial for the modulation of Prx3 and DJ-1 [79,80].
In the case of the former, SO2H formation is required to render
Prx3 inactive for extended periods of time (Fig. 2c). This allows
H2O2 to accumulate to sufﬁcient amounts to exert regulatory
effects on various proteins, either within or external to mitochon-
dria [81]. Srx has recently been identiﬁed in mitochondria indicat-
ing mitochondria are equipped with the necessary enzymatic
complement to reduce SO2H back to SH [82]. It is important to
point out though that unlike cytoplasmic Prx2, Prx3 is more
resistant to hyperoxidation [83]. Very little information exists on
the importance of SO2H groups in the redox control of proteins,
particularly in the mitochondria and which proteins and enzymes
might be involved in reduction of SO2H. New tools to properly trap
and measure SO2H in cells have been proposed including aryl-
nitroso compounds which react with SO2H with high efﬁciency
and speciﬁcity [84]. It would be intriguing to determine what
percentage of the mitochondrial proteome forms SO2H.
S-glutathionylation
Another important redox switch required to control mitochon-
drial protein function is S-glutathionylation. In these reactions,
GSH is conjugated to an exposed cysteine protein SH generating
PSSG. The S-glutathionylation of proteins in mitochondria has
been found to be highly sensitive to local changes in redox,
speciﬁcally through ﬂuctuations in 2GSH/GSSG [16,85,86].
As indicated above, the potential of the 2GSH/GSSG pair in the
matrix of mitochondria is estimated to be between 280 to
340 mV [58]. This range has been attributed to the different
methodologies used to measure and calculate absolute GSH and
GSSG levels. Most measurements of GSH and GSSG levels have
been performed using enzyme coupled assays. These types of
assays should only be used to measure total glutathione levels and
not for determination of 2GSH/GSSG since it is very difﬁcult to
accurately quantify the absolute amounts of GSSG. HPLC can also
be used which does provide a far more accurate read of 2GSH/
GSSG [86]. This is due to clean separation and resolution of GSH
from GSSG which allows easy integration and calculation of
absolute GSH and GSSG levels. Using an assumed mitochondrial
volume of 0.75 mL (considered to vary between 0.5–1 μL [8]) the
molar concentration can be calculated and then subsequently
plugged into the Nernst equation to give the potential of the pair.
However, isolation of mitochondria and treatment with acids for
glutathione extraction can artiﬁcially increase GSSG levels
decreasing the accuracy of the calculated potential. It is also
important to extract mitochondria in the presence of 25 mM
NEM to prevent any spontaneous reactions of GSH or GSSG with
protein thiols. Samples should also be injected immediately after
mitochondrial isolation since GSH can spontaneously oxidize over
time. Control experiments should also be performed with mito-
chondria treated with reducing (DTT) or oxidizing agents (H2O2)
[86]. For cells in culture, glutathione pools can be depleted using
buthionine sulfoximine (BSO) [87]. Finally, a class of Grx1-GFP
probes has been developed that allow the sensitive real-time
measurement of 2GSH/GSSG in intact cells or in vivo [88]. These
probes are targeted to the mitochondrial matrix using mitochon-
drial localization sequences. Brieﬂy, the probe works through a
series of cysteine disulﬁde exchange reactions between GSSG and
probe itself which ultimately leads to the formation of a disulﬁde
bond on GFP which alters its ﬂuorescence at 408 nm and 488 nm.
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The calculated ﬂuorescent ratio can then be used to determine the
potential of 2GSH/GSSG. A very small increase in GSSG (10 mM) or
H2O2 (12.5 mM), which produces GSSG, can induce a substantial
increase in the ratiometric ﬂuorescence of the probe [88]. The
ﬂuorescence can then be brought back down to base line with DTT.
By virtue of its extreme sensitivity and non-invasiveness (e.g. no
need to isolate mitochondria) this stands as the most sensitive and
accurate measure for 2GSH/GSSG. It is important to accurately
measure the absolute concentrations of GSH and GSSG since GSSG
can S-glutathionylate cysteine residues via a simple thiol disulﬁde
exchange reaction. Inaccurate measures of GSSG can lead to false
conclusions on the state of the redox environment and whether or
not S-glutathionylation reactions will proceed spontaneously. Thus,
it is crucial to utilize methods that provide accurate measures of
both GSH and GSSG and in this respect, spectrophotometric assays
should be avoided.
The S-glutathionylation of proteins can either proceed non-
enzymatically or enzymatically and it is thus important to distin-
guish between the two types. Non-enzymatic S-glutathionylation
can proceed via a number of different pathways (Fig. 3a). Reaction 1
simply involves a thiol disulﬁde exchange reaction between protein
cysteine S and GSSG. The result is the formation of PSSG and GSH
[89]. Reaction 1 can only proceed if GSSG has accumulated to a
sufﬁcient concentration and the 2GSH/GSSG is 1 [90]. GSSG
reaches this concentration only under oxidative stress. In reaction
2, a protein S is oxidized to SOH which then reacts with GSSG to
yield PSSG. For reaction 3, PSSG formation is initiated by the
formation of a thiyl radical which interacts with GSH to form a
glutathione anion protein thiyl radical intermediate [91]. This
structure is stabilized by O2 which subsequently yields PSSG. Non-
enzymatic glutathionylation reactions are very nonspeciﬁc and
mostly proceed under oxidative stress. Under oxidative stress
proteins in mitochondria can become hyper-glutathionylated which
is often considered a marker for oxidative damage [92].
A number of mitochondrial proteins are S-glutathionylated
under normal conditions, depending upon the tissue type
[86,93]. Further, S-glutathionylation of mitochondrial proteins
under normal conditions is cysteine thiol speciﬁc, reversible,
sensitive to changes in redox environment, and most importantly,
enzyme driven [36,90]. Enzyme-driven S-glutathionylation reac-
tions are mostly investigated in the cytosol where Grx1 has been
identiﬁed as the chief enzyme responsible for catalyzing the
deglutathionylation of PSSG. The enzymatic mechanism involves
two steps; (1) N-terminal cysteine on Grx deglutathionylates PSSG
via a thiol disulﬁde exchange reaction yielding PSH and a Grx-SSG
intermediate, (2) Grx-SSG binds GSH and the glutathionyl moiety
is removed regenerating Grx1 and producing GSSG, (3) GSSG is
reduced back to 2GSH by glutathione reductase and NADPH
(Fig. 3b) [52]. Step 1 of the enzyme mechanism is very rapid with
step 2 occurring much more slowly and is thus rate limiting [52].
It is also notable that Grx also has a C-terminal SH that can cross
react with Grx-SSG to generate an intramolecular disulﬁde bridge
and GSH. Reversal of the disulﬁde requires GSH to regenerate
Grx1-SSG in the catalytic cycle. Formation of the intramolecular
disulﬁde bridge has been suggested to serve as a site of regulation
since it may allow an S-glutathionylation on a protein to persist
[10]. The mechanistic details of the catalytic reaction still require
clariﬁcation however; several catalytic models have been pro-
posed including glutathione scaffold, glutathione activator, and an
oxidative half-reaction (reviewed in [94]).
Discussion of the catalytic cycle of Grx1 is critical since
mitochondria harbor a Grx1 isozyme, Grx2. Grx2 was only recently
identiﬁed and is classiﬁed as a dithiol Grx since it conforms to the
thioredoxin fold (four mixed β-sheets surrounded by α-helices)
and contains the CXXC catalytic motif. Intriguingly, Grx2 only has
34% sequence identity to Grx1 [53,95,96]. However, despite this
clear lack of homology, Grx2 has been found to use the precise
same catalytic mechanism as Grx1 [52]. The sequence differences
between Grx1 and Grx2 are important to the regulation of both
proteins. For instance, unlike Grx1, Grx2 has no exposed thiol
residues on its surface making it less likely to be deactivated
by ROS. Grx2 also forms a homodimer through coordination of a
2Fe-2S cluster which has been shown to be important for its
regulation [18]. Grx2 is inactive when complexed with 2Fe–2S.
Fig. 3. Non-enzymatic and enzymatic S-glutathionylation reactions and the mod-
ulation of Grx2. (a) Non-enzymatic glutathionylation reactions. (1) Solvent-exposed
thiolate is S-glutathionylated by GSSG via a thiol disulﬁde exchange reaction.
(2) Solvent-exposed thiolate are oxidized to a sulfenic acid residue by H2O2 which
then undergoes S-glutathionylation. (3) one electron reduction of a thiol forms a
thiyl radical which interacts with glutathione to form a glutathione anion thiyl
radical intermediate. A disulﬁde bond then forms between the glutathione anion
and the thiyl radical following the one electron reduction of O2 to O2 .(b) Catalytic
cycle of Grx1 and Grx2 (in diagram it is simply referred to as Grx). In step 1 Grx
catalyzes the rapid transfer of the gluthionyl moiety via a disulﬁde exchange
reaction to its catalytic cysteine which produces a Grx-SSG intermediate and a
deglutathionylated protein. Step 2 involves the GSH-mediated removal of the
glutathionyl moiety from Grx-SSG which generates a fully reduced Grx enzyme
and GSSG. For step 3 the GSSG is reduced by NADPH and glutathione reductase to
regenerate GSH. Note the side reaction for Grx-SSG in step 4 an intramolecular
disulﬁde can form in Grx. GSH is required to return Grx-SSG to its catalytic cycle.
(c) Grx2 is modulated by 2Fe–2S cluster coordination and O2 mediated dissembly
of the cluster. Grx2 is maintained is inactive as a homodimer. A subsequent burst of
O2 results in the release of active Grx2 monomers which subsequently deglu-
tathionylate target proteins. (d) Grx2 catalyzes the reversible S-glutathionylation of
Complex I. When the 2GSH/GSSG ratio is low and H2O2 is high, Grx2 glutathiony-
lase is activated. A high 2GSH/GSSG ratio and low H2O2 levels induce Grx2-
mediated deglutathionylation of Complex I.
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Disassembly of the 2Fe–2S cluster releases active monomeric Grx2
which is mediated by O2 . This illustrates that there is a tight link
between mitochondrial ROS, redox, and S-glutathionylation reac-
tions (Fig. 3c) [97]. Reassembly of the 2Fe–2S cluster and the Grx2
homodimer requires iron sulfur cluster chaperone IscU [98]. It is
also interesting that Grx2 has been found to also catalyze protein
S-glutathionylation (Fig. 3d) [85]. This occurs when the 2GSH/GSSG
is sufﬁciently oxidizing [85]. It is important to realize though that
precisely how the glutaredoxins, namely Grx1 and Grx2, catalyze
S-glutathionylation reactions is unresolved. There is though sufﬁcient
evidence to indicate that Grx2 harbors glutathionylase activity. For
instance Complex I has been documented to be S-glutathionylated and
deglutathionyated by Grx2 [85]. Grx2 has also been shown to be
required for the S-glutathionylation of uncoupling protein-3 (UCP3)
[86].The signiﬁcance of Grx2-mediated modulation of Complex I and
UCP3 by S-glutathionylation is discussed below. In addition, catalysis
of S-glutathionylation by Grx2 is feasible from a thermodynamic and
redox chemistry perspective given that thiol disulﬁde exchange
reactions are generally reversible. Hypothetically, Grx2 may only
harbor glutathionylase activity when Grx2-SSG has accumulated to a
sufﬁcient concentration. Indeed, step 2 of the catalytic cycle of Grx2 is
rate limiting and, under certain conditions, this may prompt accumu-
lation of a Grx2-SSG intermediate. It is also important to note that
glutathione S-transferase (GST; Pi and Mu-family) has recently been
found to catalyze the glutathionylation of proteins in the cytosol [99].
Mitochondria have also been reported to contain several GST isozymes
including Alpha, Kappa, Mu, Pi and Zeta have been reported suggest-
ing a similar function in mitochondria [100].
S-nitrosylation
Nitric oxide (NO) was among the ﬁrst gaseous second messen-
gers identiﬁed in mammals and plays a central role in vasodilation
[101]. Following its production by NOS, NO rapidly diffuses
through the endothelial cells, where it was produced, into smooth
muscle cells where it activates soluble guanylate cyclase which
prompts cyclic guanosine monophosphate (cGMP) production
and smooth muscle relaxation. NO is also able to interact with
mitochondria. NO binds cytochrome a3 and Cu2þB prosthetic
groups of Complex IV [60]. By binding to the heme or Cu group,
NO inhibits Complex IV activity which diminishes OXPHOS. Bind-
ing prosthetic groups is not the only way NO can modulate
mitochondria. The S-nitrosylation (SNO) of free SH residues in
proteins have also been shown to be an important component of
NO signaling. A number of different mitochondrial proteins have
been shown to be modulated by SNO. The means by which SNO is
formed, however, remains elusive. NO is not an oxidant under
biological conditions and thus cannot form a SNO via a direct
reaction with S [102]. However, NO can form a thionitroxide
group (SNHO) which, following a one-electron oxidation, can
possibly generate SNO [75]. Another mechanism for SNO involves
the initial reaction of 2 mols of NO with 1 mol of O2 to form
nitrogen dioxide (NO2). NO2 is capable of reacting with S to form
a thiyl radical which then reacts with NO to form SNO [103].
Finally, NO2 can react with NO to form dinitrogen trioxide (N2O3)
which is able to react directly with S to form SNO [104].
Where mitochondrial NO comes from is still enthusiastically
debated. First, there have been several reports that NOS isoforms
localize to mitochondria [37]. Speciﬁcally, it has been frequently
reported that nNOS is found in liver and rat brain mitochondria
where it actively produces NO following stimulation by calcium
[105]. Unfortunately, the presence of mitochondrial NOS remains
contentious since other groups have been unable to detect
any NOS isoforms in mitochondria [37]. Other sources of mitochon-
drial NO include NO generated in the cytoplasm or neighboring
cells. NO diffuses rapidly through membranes and thus can
promptly gain access to the mitochondrial matrix.
The issue surrounding external NO is the quenching of NO before
it reaches mitochondria. For instance, in normoxia, NO can be
scavenged by oxymyoglobin which produces nitrate (NO3) which
limits the amount of NO that actually reaches mitochondria [106].
Inside the cell, NO can react to form peroxynitrite (ONOO) or,
following NO2 formation, can react with unsaturated fatty acids to
produce nitro-fatty acids [107].
The debate surrounding the source of NO, and which species
actually generates SNO, does not diminish the importance of NO in
the regulation of mitochondria. SNO has been shown be important
for ischemic preconditioning and it has been shown that mito-
chondrial SNO (mSNO) can be used to greatly reduce cardiac
infarct size through reversible SNO modiﬁcation of Complex I
[108]. SNO also modulates ATP synthase, several TCA cycle
enzymes, and enzymes involved in β-oxidation [37,109]. NO has
also been shown to limit mitochondrial membrane permeability
transition (MPT) through SNO formation on cyclophillin D [110].
A number of excellent reviews have been published on the topic
NO signaling, SNO, and control of mitochondrial function
[37,111,112]. Thus, SNO and the control of mitochondrial functions
will not be considered any further in this review.
Regulation of mitochondrial biology by redox switches
From the above section it is clear that; (1) redox signaling is
very complex, (2) we still understand very little about redox
reactions, which can be attributed the lack of sensitive techniques,
(3) the importance for regulation of mitochondrial function by
redox switches. Mitochondrial ROS production, and how rapidly it
is quenched, depends on the tissue and cell type, the energetic
state of mitochondria (e.g. respiring under phosphorylating or
non-phosphorylating conditions), and which substrate is being
metabolized [93,113,114]. Regulation of mitochondria by redox
switches would also be dependent upon mitochondrial density,
protein content (e.g. thiol availability), antioxidant defense, and
glutathione availability. The 2GSH/GSSG ratio is usually in a highly
reduced state (in such tissues as heart, muscle, liver, and brain) but
the state of this redox pair can change spatially and temporally
depending upon ROS concentrations, transport of GSH from the
cytosol, export of GSSG, and reduction of GSSG back to GSH by the
efﬁcient enzymatic activity of glutathione reductase [86,115,116].
In the following section we will discuss the various mitochondrial
proteins and enzymes that are regulated by cysteine oxidation
reactions and the impact cysteine oxidation has on enzyme
function and activity. We will also highlight the conditions under
which proteins in mitochondria are modulated by cysteine oxida-
tion and the impact it has on mitochondrial metabolism and
function.
Regulation of the TCA cycle
The TCA cycle is the most central metabolic pathway for
anaerobic and aerobic organisms. For aerobes, the TCA cycle either
serves as an engine that strips electrons from nutrients for
production of ATP or provider of the necessary building blocks
for the production of biological macromolecules. A number of
enzymes in the TCA cycle have been shown to be either sulfeny-
lated or S-glutathionylated. The impact of these modiﬁcations on
mitochondrial function, and the circumstances under which
the modiﬁcation occurs, is enzyme dependent. Aconitase (Acn)
can be reversibly deactivated by H2O2 through sulfydryl group
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modiﬁcation [117]. This reversible inactivation has been shown to
occur during ischemia-reperfusion injury. Intriguingly, Acn does
not lose its 4Fe–4S cluster due to interactions with Frataxin
protein [117]. However, if the stress persists, Acn can be irrever-
sibly deactivated due to 4Fe–4S cluster disassembly [118]. NADP-
dependent isocitrate dehydrogenase (Idh) has been reported to be
inactivated by S-glutathionylation in HEK293 cells and rabbit heart
mitochondria [119]. This is intriguing since this Idh isoform is
required to contribute to the NADPH pool in mitochondria, which
provides the reducing power necessary to maintain an active
antioxidant defense system. The authors reported that half-
maximal inhibition occurred at 5 mM GSSG and can be reversed
by 10 mM DTT [119]. This would set the 2GSH/GSSG ratio to 1
and represents a system that is under oxidative stress. It would be
important to discern if this inhibition occurs under normal
conditions and how rapidly Grx2 (or another enzyme) reverses
the inhibition. As mentioned Odh is a major target for redox
regulation. Odh has been shown to be targeted by sulfenylation,
sulﬁnylation, and S-glutathionylation; the latter being important
in protecting key thiol residues from further oxidation [120]. Odh
sits at a major metabolic junction that links carbon catabolism to
amino acid production in mitochondria. It has been suggested that
reversible oxidation of Odh may be required to modulate the ﬂow
and ﬂuxes of metabolites through amino acid metabolism and the
TCA cycle. Oxidative deactivation of Odh also has the added
beneﬁt of prompting the accumulation of 2-oxoglutarate, which
has the capacity to quench H2O2 and would also aid in limiting
H2O2 production [121]. Pyruvate dehydrogenase (Pdh), which
bears dihydrolipoamide dehydrogenase subunits like Odh, can
also be modulated by mitochondrial H2O2 through thiol oxidation
[122]. In addition, like Odh, Pdh activity can be recovered with
reducing agents, illustrating that this enzyme complex is regulated
in manner similar to Odh [122]. SDH has also been found to be
controlled by S-glutathionylation [123]. However, the circum-
stances of its regulation are quite intriguing. In Sprague-Dawley
rat heart mitochondria, SDH is maintained in a glutathionylated
state [123]. Following ischemia-reperfusion, SDH is deglutathio-
nylated which not only decreases its activity but also induces a
burst of O2 production from SDH [123]. L-carnitine/acyl-carnitine
carrier (CAC) has also been found to be S-glutathionylated on
Cys136 and Cys155, respectively [124]. S-glutathionylation state of
CAC is sensitive to the potential of 2GSH/GSSG where high
GSH leads to deglutathionylation and activation of CAC and high
GSSG induces S-glutathionylation and deactivation of the trans-
porter [124]. It was also found that exogenously added Grx1
can reverse S-glutathionylation indicating that CAC may also be
targeted by either Grx1 in the intermembrane space or Grx2 in
the matrix [124]. This illustrates the complexities surrounding
S-glutathionylation and the regulation of protein function in
mitochondria.
In the above examples, S-glutathionylation has mostly been shown
to proceed under conditions of oxidative stress when GSSG levels are
high (Fig. 3a). However, it is also clear that S-glutathionylation is
reversible and occurs under normal conditions. For instance, Acn can
be reversibly deactivated by S-glutathionylation [117]. It has also been
shown that Odh can be deglutathionylated in vitro by puriﬁed Grx1
[68]. Also, SDH maintains an S-glutathionylated state in heart mito-
chondria under normal conditions [123]. The enzyme(s) that actually
mediate S-glutathionylation and deglutathionylation under these
conditions are still yet-to-be identiﬁed. However, Grx2 is a strong
candidate for mediating these reactions. In regard to sulfenylation, it is
doubtful that SOH formation plays any important regulatory role
in mitochondria due to the reactivity of this moiety, especially in
an environment rich in ROS, thiols, and glutathione. SOH is most
likely a precursor in mitochondria for other reactions such as
S-glutathionylation or sulﬁnylation.
Regulation of OXPHOS
Most of the information generated in terms of how redox
switches work to control mitochondrial proteins has been accrued
by studying the impact of S-oxidation reactions on OXPHOS. Most
of these studies have been conducted using heart mitochondria of
either bovine or mouse origin. Important information concerning
the role of redox signaling in the control of mitochondrial
bioenergetics has also been generated using cultured cells (lens
epithelia, vascular smooth muscle cells, myotubes), isolated liver
mitochondria, and isolated skeletal muscle mitochondria
[86,125,126]. The impact of chemical-induced S-glutathionylation
on mitochondrial bioenergetics has variable effects which are
dependent on cell line. Acute treatment of vascular smooth muscle
cells (VSMC) with 0.1 mM diamide, an S-glutathionylation catalyst,
induces a transient decrease in resting respiration (basal respira-
tion; respiration required to maintain cellular ATP levels under
resting conditions) which then subsequently recovers over time
[126]. Hill and colleagues also showed that 0.1 mM diamide
induced a massive increase in proton leaks in VSMC. Higher
diamide concentrations (40.25 mM) induce an irreversible
decrease in respiration [126]. These observations indicate
that aerobic respiration can indeed be modulated by reversible
S-glutathionylation reactions. Different results were obtained with
primary mouse myotubes. Treatment with r0.2 mM diamide did
not have any effect on resting respiration; however diamide
treatment did induce an increase in PMF [87]. Assessment of state
4 respiratory parameters (proton leaks; non-phosphorylating
respiration) revealed that diamide-induced S-glutathionylation
inhibited proton leaks through UCP3 [87]. Leaks through UCP3
can be reactivated by a small increase in H2O2 which is required to
decrease PMF and diminish mitochondrial ROS emission [87].
In addition, it has recently been shown that Grx2 is required to
S-glutathionylate UCP3 [86]. Indeed, UCP3 is in a deglutathiony-
lated and active state in skeletal muscle mitochondria isolated
from Grx2 knock-out (Grx2/) mice [86]. Similar results have
been obtained with Min6 insulinoma cells [16]. In this case,
chemical induction of S-glutathionylation deactivates leaks
through UCP2, a homolog of UCP3, which enhances glucose-
stimulated insulin release (GSIS) [16]. The enhancement of GSIS
is due to the maintenance of the mitochondrial protonic potential
which increases aerobic ATP production for stimulation of insulin
release. The progressive oxidation of glucose eventually leads to an
increase in mitochondrial O2 and H2O2 which deglutathionylates
UCP2, activates leaks, and desensitizes the GSIS [16]. Chemical
induction of UCP2 glutathionylation can also be used to sensitize
drug resistant cancer cells to chemotherapeutics [127]. This is due
to the fact that certain drug resistant cancer cells overexpress
UCP2 which prevents anthracycline-mediated ROS production
[128]. Induction of UCP2 S-glutathionylation deactivates proton
leaks which enhances drug toxicity through oxidative stress. Thus,
reversible S-glutathionylation can control OXPHOS, proton leaks,
and mitochondrial ROS emission which can have profound signal-
ing effects in the cell.
Complex I was the ﬁrst OXPHOS component identiﬁed to
undergo either S-glutathionylation or sulfenylation. The mechan-
ism of Complex I sulfenylation and S-glutathionylation has mostly
been explored in heart mitochondria. In terms of sulfenylation,
SOH formation was shown to undergo further oxidation to SO2H
and SO3H which irreversibly deactivates Complex I [69]. However,
cysteine residues that are oxidized to SOH in Complex I can also be
protected from further oxidation by S-glutathionylation [69].
Although S-glutathionylation decreases Complex I activity, the
modiﬁcation can be reversed [85]. Complex I S-glutathionylation
is also important since it can diminish O2 production. In bovine
heart mitochondria, Cys531 and Cys704 on the 75 KDa subunit
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NDUSF1, were identiﬁed as S-glutathionylation sites on Complex I
[69]. The NDUSF1 subunit sits in the hydrophilic arm of Complex I
in proximity of FMN NADH binding site. S-glutathionylation of the
solvent exposed Cys531 and Cys704 most likely induces conforma-
tional changes in the hydrophilic arm of Complex I which may
sterically block the NADH binding site. Thus, preventing NADH
oxidation can limit electron ﬂow through the respiratory chain and
diminish O2 production [129]. However, other studies have
shown that S-glutathionylation of Complex I actually increases
mitochondrial O2 emission [130]. This could be related to
maintenance of Complex I in a prolonged S-glutathionylated state.
It is important to connect Complex I S-glutathionylation to the
S-glutathionylation of Odh since Odh generates NADH for oxidation
by Complex I and both protein complexes produce mitochondrial
ROS (Fig. 4). Notably, the S-glytathionylation of these two protein
complexes diminishes the activity of both protein complexes when
H2O2 is high. S-glutathionylation may serve as a mechanism that
limits further O2 and H2O2 production by a mitochondrion that is
already faced with the potential threat of oxidative stress (Fig. 4)
[131,132]. Once O2 and H2O2 levels are normal, Odh and Complex I
are deglutathionylated by Grx2 and OXPHOS resumes unhindered
(Fig. 4).
Reversible S-glutathionylation of Complex I is mediated by
Grx2. Complex I has been shown to be deglutathionylated by
Grx2 in heart mitochondria, lens epithelia, and liver mitochondria
[85,86,125]. Grx2 is required to maintain Complex I in an active
deglutathionylated state in cardiac mitochondria. For instance,
mice treated with doxorubicin display increased Complex I
S-glutathionylation and decreased activity which compromises
mitochondrial ATP production [129]. Selective overexpression of
Grx2 in cardiac tissue maintains Complex I in an active deglu-
tathionylated and active state [129]. Intriguingly, Complex I is not
targeted by Grx2 in skeletal muscle mitochondria indicating that
regulation of Complex I by Grx2 is tissue-speciﬁc [86]. Grx2 is able
to catalyze the reversible glutathionylation of Complex I which is
dependent on 2GSH/GSSG [85]. A more oxidized 2GSH/GSSG ratio
induces Complex I S-glutathionylation whereas a more reduced
glutathione pool activates the deglutathionylase activity of Grx2
[85]. Thus, the S-glutathionylation serves various important roles
in the control of Complex I which include (1) protection from
irreversible oxidation and (2) control of mitochondrial ROS genesis
in response to alterations in local redox environment. The fact that
Complex I can be controlled by redox switches has made it a
pharmacological target for ischemic preconditioning and preven-
tion of heart disease [108].
OXPHOS components have been shown to be modulated by
redox switches. ATP synthase (Complex V) has been shown to be
S-glutathionylated on Cys294 on its α-subunit which is located in
the F1 hydrophilic part of the Complex [133]. This has been shown
in heart mitochondria and occurs in dyssynchronous heart failure.
Cys294 has also been shown to form SOH which reacts with a
neighboring Cys103 residue on the γ subunit to form a disulﬁde
bridge [133]. Formation of the disulﬁde bridge occurs only under
chronic heart disease. S-glutathionylation blocks nucleotide bind-
ing which diminishes the production of ATP. Garcia et al. also
showed that the α-subunit of the F1 complex of ATP synthase is
S-glutathionylated in rat brain and liver [134]. Similar to heart
mitochondria, S-glutathionylation of ATP synthase in these two
tissues diminishes ATP production. Indeed, S-glutathionylation of
Complex I and Odh not only limits NADH production but also
lowers electron ﬂow through the respiratory chain which would
effectively diminish ROS genesis. Temporary S-glutathionylation of
Complex I and Odh protects both enzyme complexes from irre-
versible oxidation when ROS is high but may also hypothetically
serve as a mechanism to diminish mitochondrial ROS production
(Fig. 4). Temporary S-glutathionylation of the F1 α-subunit of ATP
synthase may also be part of this adaptive response to a burst of
H2O2 genesis vis a vis the decrease in electron ﬂow would limit
ATP production. In addition S-glutathionylation mediated decrease
in ATP synthase activity would also limit ATP hydrolysis and the
pumping of protons back into the intermembrane space thus
preventing the repolarization of the mitochondrial inner mem-
brane (Fig. 4). The PMF is tightly associated with mitochondrial
ROS production [27]. A high protonic potential nonlinearly
increases mitochondrial ROS production by the respiratory chain
while decoupling the MIM has the opposite effect. Intriguingly,
when ROS is high in mitochondria UCP2 and UCP3 become
deglutathionylated which activates proton leaks through these
two proteins. Proton leaks lower the PMF across the MIM which
subsequently diminishes ROS production by mitochondria. Thus,
when ROS is high Complex I and Odh are S-glutathionylated to
protect from irreversible oxidation which also lowers there activity
to diminish electron ﬂow through the respiratory chain which
limits ROS production (Fig. 4). At the same time ATP synthase is
Fig. 4. Hypothetical scheme depicting the regulation of mitochondrial O2 production and OXPHOS by S-glutathionylation. When H2O2 is high and 2GSH/GSSG is low in
mitochondria, Odh, Complex I, and ATP synthase are temporarily S-glutathionylated to diminish NADH production and limit electron ﬂow through the respiratory chain.
Although this may diminish mitochondrial ATP production S-glutathionylation will limit O2 and H2O2 production by mitochondria. In addition, S-glutathionylation of ATP
synthase may also prevent ATP hydrolysis and the pumping of protons back to the intermembrane space. This would effectively maintain a lower membrane potential and
limit ROS genesis. Once ROS levels have decreased and the 2GSH/GSSG ratio is restored Grx2 deglutathionylates Complex I and potentially Odh and ATP synthase which
restores mitochondrial ATP production.
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S-glutathionylated to lower ATP production and prevent ATP
hydrolysis and MIM recoupling. Notably, S-glutathionylation of
ATP synthase may also protect cysteine residues from irreversible
oxidation. In addition, if UCP2 or UCP3 are present in the tissue,
high ROS deglutathionylates these two proteins resulting in their
activation and a lowering of mitochondrial PMF which also
diminishes ROS production. Thus, reversible S-glutathionylation
may serve as an important mechanism for the control of mito-
chondrial ROS output which can have a profound effect on cellular
ROS signaling.
Mitochondrial morphology
Mitochondrial structure and morphology plays a key role in
dictating mitochondrial function [135]. The shape of mitochondria
has a tremendous impact on mitochondrial metabolism and cell
death. Likewise the nutrients being metabolized, the concentra-
tion of nutrients in the cell, and the amount of ROS play signiﬁcant
roles in dictating mitochondrial shape and morphology [135].
In mammalian cells, the proteins involved in mitochondrial fusion,
are the integral membrane GTPases Mitofusin 1 (Mfn1), Mitofusin
2 (Mfn2) and autosomal dominant Optical Atrophy 1 (Opa1) [136].
Conversely ﬁssion is mediated by the dynamin family of GTPases
Drp-1. Chronic oxidative stress, high glucose or fatty acids (which
increase ROS), or gluco-lipotoxicity are known to induce mito-
chondrial fragmentation [135]. However, treatment with sub-
lethal amounts of H2O2 and acute stresses induce a hyperfused
state [137]. Co-treatment with antioxidants like Tempol prevents
hyperfusion [137]. Recently, Shutt et al. provided evidence that
S-glutathionylation of Mfn proteins is required to induce mito-
chondrial hyperfusion [137]. In vitro determinations showed that
addition of GSSG to reaction mixtures induced a hyperfused state
which was associated with S-glutathionylation of Mfn2 and for-
mation of Opa1 oligomers. Intriguingly, performing the same
reactions in the presence of cystosol fractions from HeLa cells
reversed Mfn2 S-glutathionylation. Redpath et al. made similar
observations showing that mitochondria in C2C12 cells adopt a
hyperfused state when treated with diamide [138]. These results
demonstrate S-glutathionylation also plays a key role in mitochon-
drial morphology and that induction of fusion is sensitive to
changes in the 2GSH/GSSG ratio. It has been proposed that
mitochondrial hyperfusion may increase resistant towards cell
stress and cell death. Hyperfusion may promote protection
through the sharing of mitochondrial resources, speciﬁcally, anti-
oxidant defense enzymes and molecules which could provide
more long term protection of mitochondrial proteins, enzymes,
DNA, and lipids from acute stressors. Effectively, this protective
response would also prevent oxidative stress and induction of
intrinsic apoptotic cascades via preservation of mitochondrial
redox balance.
MTP and redox switches
Oxyradicals are maintained at low concentrations by antiox-
idant defense systems. But what happens if oxyradical production
cannot be controlled and antioxidant defense systems are over-
whelmed? In this scenario, mitochondria induce cell death path-
ways. The mitochondrial intermembrane space contains several
factors, including Smac/DIABLO, apoptosis inducing factor, and
cytochrome C, that upon being released into the cytoplasm,
activate programmed cell death pathways [139]. The use of
cytochrome C as an apoptogenic signaling molecule is especially
interesting since it is a key component of OXPHOS machinery. This
illustrates the tight relationship between the efﬁciency of electron
ﬂow through the ETC and the production of either ATP or ROS.
Release of these apoptogenic factors in the cytoplasm can be
mediated by MPT. The mitochondrial permeability transition pore
(MPTP) is a non-selective pore that allows the free diffusion of
molecules o1.5 KDa in size [140]. Once open, the MPTP dissipates
ion and metabolite gradients and collapses the PMF, which can
induce massive swelling of mitochondria and the rupture of the
mitochondrial outer membrane [70]. The MPTP is normally closed
but can be opened by a number of factors including elevated
matrix [Ca2þ], adenine nucleotide depletion, and increased inor-
ganic phosphate concentration [141]. Notably for the purpose of
redox switches, MPT can also be induced by ROS, hydroperoxides
(t-butyl hydroperoxide), and chemical toxins (which can induce
ROS production) [141]. Antioxidant supplementation prevents
MPT. Interestingly, MPT can also be modulated by SH blockers and
S-glutathionylation catalysts. For instance, induction of MPT can be
prevented by incubating mitochondria in N-ethylmaleimide
(NEM), a Michael acceptor that covalently binds to SH [70].
Alternatively, MPT can also be induced by diamide [70]. Studies
using semiquinone, which actively produces O2 , have found that
mitochondrial produced ROS can activate MPT [142,143]. In addi-
tion, it has also been shown that H2O2 is the oxyradical species
that most likely induces MPT since inclusion of catalase and thiol
peroxidases to reaction mixtures prevents MPT [143,144]. Thus,
the capacity of mitochondria to induce programmed cell death
depends on redox switches which, upon sulfenylation and/or
S-glutathionylation, induces pore opening.
The function of redox switches in pore opening has been
reviewed recently in [145]. Redox switches most likely serve as
the connection between regulation of mitochondrial function and
induction of death. The composition of MPTP still remains a
contentious issue. MPTP has been shown to be composed of
ANT, voltage dependent anion channel (VDAC), Pi carrier, and
cyclophilin D (Cyp-D) [146]. For pore opening to occur, Cyp-D
needs to bind to the protein complex. The role of ANT in MPT is
enthusiastically debated however; several reports have conclu-
sively shown that oxidation of key cysteine residues on ANT is
required for pore opening. Pore opening was shown to require the
cross-linking of Cys160 and Cys257 (rat) or Cys256 (bovine) in ANT
[70]. This type of cross-linking only occurs if one of the SH groups
is oxidized to SOH. Intriguingly, blocking Cys160 with adenine
nucleotides actually prevents pore opening; most likely through
prevention of disulﬁde bond formation [70]. Prolonged exposure
to high (4100 mM) concentrations of H2O2 can decrease mito-
chondrial ATP production which could lead to a decreased amount
of adenine nucleotide binding on ANT which would then exposed
Cys160 for oxidation and subsequent disulﬁde bond formation. It is
also important to point out that mitochondrial solute anion
carriers share a high degree of homology including a Cys residue
(Cys256) in the last loop region that contacts the matrix. It was
recently reported that ANT can also be S-glutathionylated and
maintains an S-glutathionylated state in mitochondria from pri-
mary astrocytes and rat cortex [147]. Following oxidative stress,
ANT is deglutathionylated which leads to MPT and induction of
cell death [147]. Thus, it is possible that S-glutathionylation of ANT
may prevent cysteine oxidation and cross-linking of Cys160 and
Cys256/257. However, several key aspects surrounding ANT, cysteine
oxidation, and pore opening need to be resolved such as (1)
S-glutathionylation can also potentiate Cys cross-linking and
(2) does ANT actually form part of MPT. Indeed, the actual
composition of MPTP is still enthusiastically debated and remains
a subject of heavy scrutiny. It has been shown that ANT and VDAC
are not required for pore formation. Various reports however have
shown that Pi carrier may be a key part of the MPTP [148] but this
has also been refuted [149]. It was also recently reported that
MPTP is actually composed of ATP synthase dimers [150]. Since
ATP synthase is amenable to cysteine oxidation when ROS is high
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it would be intriguing to determine if the oxidation of cysteines on
ATP synthase is required to potentiate dimer formation.
Cyp-D has also been found to be modulated by S-oxidation
reactions [151]. In this case, S-glutathionylation prevents Cyp-D
binding to ANT which blocks MPT [151]. This modiﬁcation
was found to occur on Cys203 [110]. It is intriguing that
S-glutathionylation of Cyp-D actually prevents MPTP. As mentioned
above the actual composition of the MPTP is still enthusiastically
debated however; Cyp-D has so far been the only component of
MPTP found to be indispensable for pore opening. Cyp-D knockout
or inhibition with cyclosporine A prevents MPTP and apoptosis
[152,153]. Since S-glutathionylation of Cyp-D prevents pore opening
it is possible that blocking Cys residues on Cyp-D may be a
protective response, e.g. when ROS production is transiently highly
S-glutathionylation of Cyp-D prevents pore opening. Indeed,
a transient burst of H2O2 production by mitochondria also
S-glutathionylates Odh and Complex I which may effectively limit
mitochondrial ROS production (Fig. 4). In conjunction with this,
S-glutathionylation of Cyp-D may be required to prevent pore
opening while mitochondria adapt to the transient increase in
mitochondrial ROS production [110]. The involvement of ANT in
pore opening is more contentious since some studies have shown
that knockout of ANT does not diminish or prevent MPT [154].
However, it is possible that other proposed components of MPTP
may be required to sense surrounding changes in redox and
participate in pore formation following cysteine oxidation.
Deregulation of mitochondrial thiol reactions in disease
Cardiovascular diseases
An increasing number of studies have found that mitochondrial
thiol oxidation is involved in cardiac arrest and stroke. Cessation of
blood ﬂow to a portion of the heart or brain results in localized
hypoxia and often injury is observed during the reperfusion of
oxygenated blood (ischemia/reperfusion injury or IRI). Injury mediated
through the reperfusion stage is a result of the generation of ROS and
RNS, although the sources of these are currently debated [155–157].
A key feature of IRI is mitochondrial energetic dysfunction [158]. ROS
and RNS, generated during IRI, have been shown to damage compo-
nents in Complexes I, III, IV and V of the respiratory chain, as well
as many Kreb Cycle enzymes [159,160]. Short ischemic periods
precondition tissues to hypoxic exposure and provide cardio- and
neuronal-protective effects (ischemic preconditioning). These effects
are mediated through the expression of protective genes and proteins
that remain in the cell long after the cessation of ischemic stress. Thiol
modiﬁcations, particularly of Complex I subunits, have been identiﬁed
during IRI and results in further ROS generation by this Complex [158].
It was also found that cysteine 90 of the 70 kDa FAD-binding protein
of mitochondrial succinate ubiquinone reductase, or Complex II, was
glutathionylated and that this modiﬁcation (as well as electron
transfer activity of the respiratory chain itself) was markedly decreased
in post-ischemic heart during IRI [123]. A complete assessment of
mitochondrial thiol-containing proteins that become oxidized during
IRI in Langendorff perfused mouse heart has recently been carried out
using mass spectrometry with isotope-coded afﬁnity tags (ICAT) [161].
S-glutathionylation of Complex I increases when GSSG levels are high
which subsequently decreases the activity of this respiratory complex
[10]. In addition, a recent report has also shown that high GSSG
induces S-glutathionylation and deactivation of CAC [124]. Since IRI
also increases GSSG it would be important to determine if IRI also
leads to the aberrant S-glutathionylation and deactivation of Complex I
and CAC.
Enhancement of protein S-nitrosylation in the myocardium is
marked in the post-ischemic heart [162–164]. RNS have been
found to have both damaging and protective effects on myocardial
tissues. Peroxynitrite-mediated tyrosine S-nitrosylation of the
70 kDa FAD-binding protein of Complex II occurs in the post-
ischemic myocardium [165]. S-nitrosylation of Tyr56 and Tyr142
occurred while Cys267, Cys476, and Cys537 were involved in
peroxynitrite-mediated S-sulfonation. Peroxynitrite-mediated dis-
ulﬁde formation was also found to occur between Cys306–Cys312,
Cys439–Cys444, and Cys288–Cys575.
In other reports, a wide variety of nitric oxide donors and
S-nitrosylating agents have been found to protect the ischemic
myocardium from infarction. In this respect, S-nitrosylation
of mitochondrial proteins during ischemia-reperfusion has cardio-
protective effects. S-nitrosylation of Cys39 on the NADH-ubiquinone
oxidoreductase chain 3 (ND3) subunit of Complex I occurs only after
ischemia [108]. Reversible D-nitrosylation of this protein slows the
reactivation of mitochondria during the crucial ﬁrst minutes of
reperfusion of heart tissue, thereby decreasing ROS production.
Likewise, S-nitrosylation of Cys137 of the 75 kDa Complex I subunit
was found to occur [166]. The implications of this are that ROS will
decrease upon reperfusion. It has been previously shown that
inhibition of Complex IV by NO can cause the back-up of electrons
along the electron transport chain and increase ROS generation at
Complex III [167,168]. Since Complex I is the entry point for
electrons into the chain, reversible inhibition of Complex I by S-
nitrosylation would lower electron ﬂux into the chain and thus
lower ROS generation from the chain itself. Although inhibition of
Complex I may increase generation of ROS from the complex itself
[130], ROS generated from Complex I has been found to be much
less than that generated from Complex III [169].
Mitochondrial thiol modiﬁcation may also alter the timing, or
synchrony, of contractions in the heart. Large differences in the
timing of contractions can reduce cardiac output and efﬁciency
and result in dyssynchronous heart failure (DHF). Mixed disulﬁde
bond formation of mitochondrial F1FO-ATP synthase subunits have
been found to be involved in DHF [133]. Two cysteine disulﬁde
bond oxidations were identiﬁed to be involved in DHF. The ﬁrst
was a disulﬁde linkage between cysteine Cys294 of the α-subunit
and Cys103 of the γ-subunit. The second was an oxidation of Cys294
to sulfenic acid. In addition, Cys294 of the α-subunit can also be
S-glutathionylated and S-nitrosylated [170]. Either thiol modiﬁca-
tion led to a signiﬁcant decrease in ATP synthase activity, resulting
in the development of DHF. Glutathionylation of Cys294 of the
α-subunit also has the potential to block nucleotide binding and
thus decrease activity [171].
Metabolic syndrome, insulin resistance, obesity and diabetes
Diabetes is a major health risk, with the global population of
diabetics estimated to reach 300 million by the year 2025.
Mortality risk is complicated by the association of diabetes
mellitus and myocardial infarction. Diabetes is associated with
hyperglycemia and this has been shown to have a direct effect on
mitochondrial function [172]. The mitochondria from diabetic
hearts have been found to be sensitized to mitochondrial perme-
ability transition pore opening, which leads to a propensity for
cardiac injury in diabetic patients and in animal models [173,174].
Hyperglycemia leads to high glucose-dependent production of
electron transfer donors (NADH and FADH2) and thereby increases
electron ﬂux through the mitochondrial electron transport chain.
Consequently there is an increase in the ATP/ADP ratio and
hyperpolarization of the mitochondrial membrane potential
results. This high electrochemical potential leads to a partial
inhibition of electron transport at Complex III, leading to an
accumulation of electrons on Q. This, in turn, drives the partial
reduction of O2 to generate O2 . The generation of O2 from the
highly reduced Q, and from Complex III in general, is believed to be
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the primary source of mitochondrial dysfunction during diabetes.
Two recent reviews have addressed the role of redox signaling and
S-glutathionylation in glucose-stimulated insulin release and how
deregulated redox signaling could potentially be related to devel-
opment of diabetes [175]. However, very few studies have actually
addressed the role of redox signaling in modulation mitochondrial
function in pancreatic β-cells. A recent report has shown that
reversible S-glutathionylation is required to control proton leaks
through UCP2 in mitochondria which plays a role in regulating
glucose-stimulated insulin release in Min6 cells and pancreatic
islets [16].
Nutrient excess leads to excessive levels of energy substrates
utilized by the mitochondria with consequential effects on lipid
and glucose metabolism. This, in turn, leads to mitochondrial
dysfunction and to the development of obesity and obesity-related
pathologies such as non-alcoholic fatty acid liver disease (NAFLD)
[176]. Few studies have addressed the relationship between
deregulated redox signaling and the development of metabolic
disease. A recent report has shown that the S-glutathionylated
proteome in hepatic and visceral adipose tissue changes drastically
upon the onset of obesity in mice [177]. In addition, knock-out of
Grx2 leads to a signiﬁcant decrease in total adiposity in C57Bl6J
mice [86]. Intriguingly the decrease in adiposity in Grx2/ mice
correlates strongly with an increase in mitochondrial respiration,
nutrient oxidation, and proton leaks through UCP3 in skeletal
muscle [86]. It has been suggested that increasing leaks through
UCP3 may have a weight loss effect since an increase in leaks
would inevitably increase respiration and nutrient oxidation [178].
Thus, the weight loss effect observed in Grx2/ mice may be
due to the maintenance of UCP3 in a deglutathionylated and active
state which ultimately leads to increases proton leaks and nutrient
metabolism. Previously, it was found that mitochondria from
obese rats show an increased capacity for oxidizing succinate,
likely due to increased activity of succinate dehydrogenase, the
mitochondrial enzyme that oxidizes succinate and reduces Q [179].
Oxidized succinate, or fumarate, can form a Michael addition with
thiol groups in proteins [180] and this post-translational modiﬁca-
tion of proteins has been found to inactivate glyceraldehyde-
3-phosphate dehydrogenase. Increased succination of protein
thiols in observed during obesity and diabetes [181]. Succination
of protein thiols in adipocytes has been found to occur during
mitochondrial stress in adipocytes during adipogenesis [182].
S-(2-succinyl)cysteine (2SC), the product of chemical modiﬁcation
of proteins by the Krebs cycle intermediate, fumarate, was found
to be signiﬁcantly increased during maturation of 3T3-L1 ﬁbro-
blasts to adipocytes. Treatment of 3T3 cells with high glucose
(30 mM) caused a signiﬁcant increase in cellular ATP/ADP ratio,
NADH/NADþ ratio and mitochondrial membrane potential [183].
It also increased total cellular protein succination, but mitochon-
drial proteins alone were not examined in this study. Recently,
mitochondrial Acn was found to be inhibited by succination in
fumarate hydratase deﬁciency occurring in hereditary leiomyoma-
tosis and renal cell cancer [184]. It remains to be determined
whether a similar inhibition occurs during diabetes and obesity.
Neurodegenerative diseases
The major neurodegenerative diseases, including Alzheimer0s
(AD), Friedreich0s (FD), amyotrophic lateral sclerosis (ALS or Lou
Gehrig0s), Huntington0s (HD), Parkinson0s (PD) and multiple sclero-
sis (MS) diseases, are characterized by a progressive loss of
neurons and glutathionylation of proteins have been shown to
have a role in this process [185]. All are characterized by either
misfolded (e.g. tau), misprocessed (eg. amyloid precursor protein)
or mutated (eg. α-synuclein) proteins. These proteins (or peptides
from proteins) form insoluble aggregates and mitochondrial
dysfunction, with corresponding generation of ROS and RNS, has
been implicated in the process. The role of mitochondrial protein
thiols in the development of neurodegenerative diseases is not
fully understood and is an area that requires active investigation.
The levels of GSH have been reported to be reduced in AD
[186]. Likewise, similar changes were observed in PD where GSH
was reduced and GSSG was increased [187,188]. PD is character-
ized by early GSH depletion in dopaminergic cells in the substantia
nigra (SN). The reasons for depletion of GSH in neurodegenerative
diseases are not always clear. In PD, there is no corresponding
increase in GSSG [189], so GSH depletion cannot be explained by
oxidative stress alone. In this study, there was no increase in
glutathione synthase activity in PD, but a large increase in
γ-glutamyltranspeptidase, an enzyme that catalyzes the transfer
of the γ-glutamyl moiety from GSH or a glutathione conjugate
onto an acceptor molecule, was observed. As mentioned pre-
viously, mitochondrial GSH is a substrate for mitochondrial Grx.
Grx2 has been shown to be involved in mitochondrial iron–sulfur
(Fe–S) center biogenesis [190]. Increased cellular iron levels are a
hallmark of PD, and decreased levels of GSH in PD results in a
depletion of substrate for Grx2. The result is decreased iron
incorporation into mitochondrial Complex I and aconitase (Acn)
[190]. It also results in signiﬁcant increases in iron-regulatory
protein (IRP) binding, transferrin receptor, decreased ferritin, and
subsequent increases in mitochondrial iron levels. Decreases in
GSH, and increased levels of GSSG and nitrosothiols, were also
observed in MS patients [191].
Glutathionylation of mitochondrial proteins has been shown to
be involved in neurodegenerative disorders. Glutaredoxin (Grx) is
responsible for the deglutathionylation of proteins and has been
shown to be decreased in post-mortem AD brains [192]. Loss of
Grx would mean loss of the cell0s ability to deglutathionylate
proteins as well as its ability to bind to apoptosis signal-regulating
kinase 1 (ASK1) (also known as mitogen-activated protein kinase
kinase kinase 5 (MAP3K5)). In a mouse model of PD (acute
treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) which targets mitochondrial Complex I), Grx was observed
to increase in brains [193]. When Grx1 was knocked down by
antisense oligonucleotides, inactivation of Complex I by MPTP was
not observed. It is also interesting to note that glutathionylation of
the tau protein causes it to polymerize and form the neuroﬁbril-
lary tangles [194] found in AD.
S-nitrosylation of mitochondrial proteins has been related to
the development of neurodegenerative disorders. S-nitrosylation
of mitochondrial Complex I has previously been implicated in the
development of PD [195,196]. Protein disulﬁde isomerase (PDI), a
thioredoxin-like domain protein closely related to Grx and Trx, has
also been implicated in PD [197]. PDI can become S-nitrosylated
(forming SNO-PDI) and this modiﬁcation disrupts both its chaper-
onin and neuroprotective functions in PD [198] and in AD [199].
The S-nitrosylation of dynamin-related protein 1 (Drp1) may be
related to the pathological fragmentation of mitochondria and
consequent loss of synapses in neurodegenerative disorders [197].
Drp1 controls mitochondrial ﬁssion, and is responsible for proper
neuronal development. Drp1 knockout mice exhibit abnormal
brain development and die around embryonic day 12. Mitochon-
drial fusion/ﬁssion is essential for maintaining mitochondrial
integrity and disruption of these processes leads to mitochondrial
dysfunction and the development of PD and AD [200,201]. NO,
produced in an inﬂammatory response to the Aβ peptide, nitrosy-
lates a key cysteine on Drp1 [199], resulting in mitochondrial
ﬁssion, synaptic loss, and neuronal damage. Prevention of
S-nitrosylation of Drp1 by cysteine mutation abrogates these
neurotoxic events. However, the role of Drp1 S-nitrosylation in
its GTPase activity, mitochondrial ﬁssion and neuronal injury in AD
remains debated as other reports have found that S-nitrosylation
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of Cys644 of Drp1 does not affect its GTPase activity or cause
dimerization of the protein [202].
Aging
All organisms undergo aging and mitochondrial protein thiol
group content may play a role in this process [203,204]. Aging has
been associated with more oxidized forms of biomacromolecules,
particularly in the mitochondria where the majority of ROS/RNS
are produced within the cell [205–207]. Previously, it has been
shown that mitochondrial Complex I activity decreases with age
and that protection of thiol groups with N-acetylcysteine pre-
vented such decrease [208]. In an interesting study done on one
short-lived and one long-lived strain (48% longer) of mouse,
mitochondrial thiols (glutathione, reactive protein thiols) were
found to be lower in short-lived mice (with corresponding higher
levels of GSSG) than in long-lived mice [209]. Peroxiredoxin III,
present in the mitochondria, was found to be present in it more
oxidized, inactive form in aged rats [210]. Cysteine 109 in the
catalytic site was found to be more sulfonated in aged animals. Not
all modiﬁcations, associated with age, are viewed to be detrimen-
tal, with some being beneﬁcial to the aging cell [211].
Age-related declines in GSH result in more oxidizing conditions
within plasma[212]. It also means that there may be less available
for glutathionylation within mitochondria, and thus proteins
would be less glutathionylated during oxidizing conditions.
Glutathionylation has been found to have both inactivating effects
on its function [213,214], but may also protect the modiﬁed
protein (due to the reversibility of glutathionylation) from irrever-
sible and permanent damage [68].
The S-nitrosylation of proteins with age has been well studied,
but a lack of a focus has been made on the mitochondria.
S-nitrosylation of general cellular proteins linked to neurodegen-
erative diseases [215], cardiovascular diseases [216], obesity and
diabetes [217] have all been related to aging. Likewise, general
glutathionylation of cellular proteins has been associated with
age-related diseases [218]. Succination and disease has not been
studied in great detail, but mitochondrial sirtuin 5 has been
previously shown to desuccinylate mitochondrial proteins [219].
Such modiﬁcations could be elucidated by performing proteomic
work on pure isolated mitochondrial preparations. The challenge
is that current protocols for such preparations do not yield fully
pure mitochondria due to the nature in the cell (mitochondria
form a syncytium throughout the cell and not a distinct organelle).
The regulation of mitochondrial abundance and function by
thiol modiﬁcation in disease is an unexplored realm of research
that is open for investigation. Nitrosylation, sulfonylation, glu-
tathionylation and succination of protein thiols represent rapid
posttranslational “switches” controlling the function of mitochon-
drial proteins and providing a “fast” response to environmental
stimuli. Discovery of additional thiol modiﬁcation targets in the
mitochondria should help us attain a more complete understand-
ing of the molecular processes by which these modiﬁcations occur.
Further elucidation of the mechanism by which these controls
alter function opens up new avenues for the development of
thiol-based therapeutics and antioxidants for the treatment of
mitochondrial dysfunction in aging and disease.
Conclusions and perspectives
Mitochondria fulﬁll a multitude of essential cellular functions
which are ultimately dependent on the production of ATP and
ROS. ATP is required to drive most cellular processes while ROS
can serve as an important signaling molecule. Genesis of either
molecule is dependent on the transfer of electrons from nutrients to
O2 in the ETC. Mitochondrial dysfunction is related to wide range of
diseases and some cases is actually the cause of disease. In the
present review we have outlined the importance of redox signals in
the modulation of mitochondrial function and how deregulation of
the signals can lead to development of various disease states. Key
enzymes and proteins involved in nutrient oxidation, metabolism,
OXPHOS, solute transport, ROS production, ROS quenching, mito-
chondrial morphology, and even apoptosis are modulated by
S-oxidation, S-glutathionylation, and S-nitrosylation. We illustrated
the complexity of these reactions since ROS, GSH, and NO converge
on protein cysteine thiols resulting in oxidation and change in
protein function. We also showed that these modiﬁcations occur
under to scenarios (1) controlled reactions which are site speciﬁc,
rapid, and readily reversed by enzymes and (2) uncontrolled
reactions which are nonspeciﬁc and associated with oxidative stress
and deregulated redox signaling. We also discussed some emerging
concepts in terms of mitochondrial medicine and how the concept
of mitochondria-targeted pharmaceuticals can potentially be utilized
to restore deregulated redox signaling through replenishment of
mitochondrial GSH and/or restoring mitochondrial ROS levels.
Notably, we overlooked some other important reactions such as
formation of persulﬁdes (Cys–S–S) which are the result of H2S
signaling. Indeed, mitochondria are not only sensitive to H2S
signaling but also important sites for H2S metabolism [220,221].
Much remains to be investigated in terms of redox signaling and the
modulation of mitochondrial function. However, based on present
knowledge it is clear that redox signaling plays a central role in
modulating mitochondrial biology and physiology.
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